Literature DB >> 9795829

Bladder tumor markers: need, nature and application. 2. Tumor and tumor-associated antigens.

M M Kirollos1, S McDermott, R A Bradbrook.   

Abstract

Despite the diversity of the available markers, none is truly specific to transitional epithelium, let alone its tumors. Some of the markers used, such as hCG and CEA, are far better known in other fields and seem to be expressed in only a minority of urothelial tumors. The majority of the available markers are tumor associated and should perhaps be considered as by-products of the process of malignancy in the urinary tract. Newer tests which are simple, rapid and easy to use have a practical advantage. These are currently the Bard BTA, BTA Stat and Aura-Tek FDP tests. So far, these markers have achieved only an arguable and marginal role in daily clinical practice, challenging the role of cytology and helping decide the type of cystoscopy. A more substantial role awaits a test with higher and more consistent sensitivity and specificity, together with the capability to provide independent diagnostic and/or prognostic information. In this part of the review we examine the literature view of the above-mentioned tests, as well as other new and some older tests such as blood group-related antigens, Lewis antigen, cytokeratins and others.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9795829     DOI: 10.1007/bf01901609

Source DB:  PubMed          Journal:  Int Urogynecol J Pelvic Floor Dysfunct


  49 in total

1.  Tumor-derived hyaluronidase: a diagnostic urine marker for high-grade bladder cancer.

Authors:  H T Pham; N L Block; V B Lokeshwar
Journal:  Cancer Res       Date:  1997-02-15       Impact factor: 12.701

2.  Cytokeratin 20 as an objective marker of urothelial dysplasia.

Authors:  P Harnden; I Eardley; A D Joyce; J Southgate
Journal:  Br J Urol       Date:  1996-12

3.  Carcinoembryonic antigen and urothelial carcinoma.

Authors:  R R Hall; D J Laurence; A M Neville; D M Wallace
Journal:  Br J Urol       Date:  1973-02

Review 4.  Critical appraisal of tumor markers in bladder cancer.

Authors:  Y Fradet; C Cordon-Cardo
Journal:  Semin Urol       Date:  1993-08

5.  Significance of serum laminin P1 values in patients with transitional cell carcinoma of the bladder.

Authors:  U Mungan; G Kirkali; I Celebi; Z Kirkali
Journal:  Urology       Date:  1996-09       Impact factor: 2.649

6.  Ectopic human chorionic gonadotrophin (HCG) production: is the detection by serum analysis of HCG of clinical relevance in transitional cell carcinoma of the bladder?

Authors:  D J Smith; H J Evans; J Newman; C R Chapple
Journal:  Br J Urol       Date:  1994-04

7.  Is beta-human chorionic gonadotrophin production by transitional cell carcinoma of the bladder a marker of aggressive disease and resistance to radiotherapy?

Authors:  G Moutzouris; D Yannopoulos; C Barbatis; A Zaharof; C Theodorou
Journal:  Br J Urol       Date:  1993-12

8.  Rapid detection of bladder cancer: a comparative study of point of care tests.

Authors:  B Johnston; A Morales; L Emerson; M Lundie
Journal:  J Urol       Date:  1997-12       Impact factor: 7.450

9.  Urine laminin P1 assessment discriminates between invasive and noninvasive urothelial cell carcinoma of the bladder.

Authors:  K M Abou Farha; P P Menheere; F H Nieman; R A Janknegt; J W Arends
Journal:  Urol Int       Date:  1993       Impact factor: 2.089

Review 10.  Detection of bladder tumors by immunostaining of the Lewis X antigen in cells from voided urine.

Authors:  D Golijanin; Y Sherman; A Shapiro; D Pode
Journal:  Urology       Date:  1995-08       Impact factor: 2.649

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.